# ANTIVIRAL DRUGS TO CURE CHRONIC HEPATITIS B VIRUS INFECTION

> **NIH NIH N01** · HBVTECH · 2022 · $1,499,999

## Abstract

To support a Phase II proposal to develop a new hepatitis B virus (HBV) cure drug. The Phase II proposal seeks to expand on the development of the lead compound supported under a Phase I study.

## Key facts

- **NIH application ID:** 10706433
- **Project number:** 75N93022C00042-0-9999-1
- **Recipient organization:** HBVTECH
- **Principal Investigator:** YANG-YUAN ZHANG
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $1,499,999
- **Award type:** —
- **Project period:** 2022-09-01 → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10706433

## Citation

> US National Institutes of Health, RePORTER application 10706433, ANTIVIRAL DRUGS TO CURE CHRONIC HEPATITIS B VIRUS INFECTION (75N93022C00042-0-9999-1). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10706433. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*